Homepage

Apimeds Pharmaceuticals US, Inc

APUS AMEX Categories PDF
Healthcare · Drug Manufacturers - Specialty & Generic · United States · Updated May 10, 8:17pm
$1.51
Price
$1.9M
Market Cap
2
Employees
-0.52
Beta
Vinod Menon
CEO
Business Description

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.

Business History
Price Overview
Last updated: May 11, 2026 1:51pm (just now)
$1.45
-0.06 (-4.20%)
Day Range
$1.34 – $1.57
52-Week Range
$1.34 – $40.31
50-Day MA
$7.05
200-Day MA
$16.12
Volume
5,170.00
Share Structure
Outstanding 1,257,598.00
Float 226,548.00
Free Float 18.0%
Low free float — 18.0% of shares trade freely, ~82% held by insiders/institutions
Below average liquidity. Large orders can move the price significantly. Insiders or strategic holders control the majority — watch for lockup expirations or secondary offerings.
Small absolute float (0.2M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-2.75
Stock Price: $1.51
EPS (Diluted): -0.55
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
0.00
Stock Price: $1.51
Total Equity: $153.35B
Shares: 10,882,000
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
-1,074.38
Market Cap: $1.90M
Total Debt: $7.77B
Cash: $1.64B
EBITDA: -$11.91B
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$6.2B
Market Cap: $1.90M
Total Debt: $7.77B
Cash: $1.64B
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
0.0%
Gross Profit: -$5,706
Revenue: $0.00
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
0.0%
Operating Income: -$11.91M
Revenue: $0.00
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
0.0%
Net Income: -$6.00B
Revenue: $0.00
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
0.0%
Net Income: -$6.00B
Total Equity: $153.35B
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
0.0%
Operating Income: -$11.91M
Tax Rate: 0.0%
Equity: $153.35B
Total Debt: $7.77B
Cash: $1.64B
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
1.31
Current Assets: $13.98B
Current Liabilities: $10.71B
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.05
Short-Term Debt: $7.64B
Long-Term Debt: $129.45M
Total Debt: $7.77B
Total Equity: $153.35B
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 10,882,000
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$14,091.88
Total Equity: $153.35B
Shares: 10,882,000
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-0.83
Operating CF: -$8.93M
CapEx: -$57,333
Shares: 10,882,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.51
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$6.00B
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares APUS against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $0 $0 $0
Cost of Revenue $0 $0 $0 $0 $5,706
Gross Profit $0 $0 $0 $0 $-5,706
Operating Expenses $1.0M $639,529 $747,436 $1.3M $11.9B
Operating Income -$1.0M $-639,529 $-747,436 -$1.3M -$11.9M
Net Income -$1.0M $-668,666 $-777,694 -$1.4M -$6.0B
EBITDA -$1.0M $-639,529 $-739,625 -$1.3M -$11.9B
EPS $-0.89 $-0.58 $-0.68 $-1.20 $-0.55
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $171,438 $6,171 $410,481 $3,455 $1.6B
Total Current Assets $172,169 $6,171 $422,076 $13,057 $14.0B
Total Assets $172,169 $6,171 $422,076 $13,057 $164.2B
Current Liabilities $10,652 $319,777 $123,314 $1.0M $10.7B
Long-Term Debt $400,000 $400,000 $266,891 $346,844 $129.5M
Total Liabilities $410,652 $719,777 $390,205 $1.4M $10.8B
Total Equity $-238,483 $-713,606 $31,871 -$1.4M $153.3B
Retained Earnings -$1.6M -$2.2M -$3.0M -$4.4M -$10.4B
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-823,114 $-448,167 $-627,790 $-733,526 -$8.9M
Capital Expenditure $0 $0 $0 $0 $-57,333
Free Cash Flow $-823,114 $-448,167 $-627,790 $-733,526 -$9.0M
Acquisitions (net) $0 $0 $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash $-423,114 $-165,267 $404,310 $-407,026 $9.6M
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth — — — —
Gross Profit Growth — — — —
Operating Income Growth +37.3% -16.9% -70.6% -834.2%
Net Income Growth +34.8% -16.3% -78.7% -431,639.6%
EBITDA Growth +37.3% -15.7% -72.0% -936,222.7%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2024-05-12 Inscobee Inc. 0.00 $0.00 $0
2025-11-11 Weintraub Bennett A-Award 10,000.00 $2.67 $26,700
2025-11-11 Yoon Hankil A-Award 10,000.00 $2.67 $26,700
2025-11-11 Koo Jakap A-Award 10,000.00 $2.67 $26,700
2025-11-11 O'DONNELL CAROL A A-Award 10,000.00 $2.67 $26,700
2025-11-11 Kogan Elona A-Award 10,000.00 $2.67 $26,700
2025-10-15 Kogan Elona A-Award 3,000.00 $1.92 $5,760
2025-10-15 O'DONNELL CAROL A A-Award 3,000.00 $1.92 $5,760
2025-10-15 Koo Jakap A-Award 3,000.00 $1.92 $5,760
2025-10-15 Weintraub Bennett A-Award 3,000.00 $1.92 $5,760
2025-10-15 Kim Christopher A-Award 3,000.00 $1.92 $5,760
2025-10-15 Yoon Hankil A-Award 3,000.00 $1.92 $5,760
2025-10-15 Emerson Erik C. A-Award 215,000.00 $1.92 $412,800
Community AI Feedback
Sign in to Contribute
No community reviews yet for APUS. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27